7 completed, 1 terminated, 1 withdrawn. 5 Phase 3, 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow briakinumab: new trials by email Literature Review of briakinumab trials Research Report on briakinumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates. briakinumab - Moderate to Severe Plaque Psoriasis | Phase 1 | Withdrawn | Abbott | 12 | 2011-04-01 | 2011-10-21 |
| Phase 1 BA Study, Single Center With Healthy Volunteers ABT-874 - Healthy | Phase 1 | Completed | Abbott | 75 | 2009-01-01 | 2010-11-08 |
| Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis ABT-874, etanercept, placebo - Moderate to Severe Plaque Psoriasis | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 350 | 2008-07-01 | 2013-01-18 |
| Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis ABT-874, etanercept, placebo - Plaque Psoriasis | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 347 | 2008-05-01 | 2013-01-21 |
| A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis ABT-874, Methotrexate - Psoriasis | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 317 | 2008-04-01 | 2013-01-29 |
| Open Label Continuation Study in Moderate to Severe Psoriasis ABT-874 - Moderate to Severe Plaque Psoriasis | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 2301 | 2008-02-01 | 2013-01-30 |
| Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease Placebo, ABT-874 - Crohn's Disease | Phase 2 | Terminated | Abbott | 246 | 2007-11-01 | 2011-08-23 |
| A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis Placebo, ABT-874 - Plaque Psoriasis | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 1465 | 2007-11-01 | 2013-02-08 |
| Monoclonal Antibody Treatment of Crohn's Disease J695 - Crohn's Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 40 | 2000-12-01 | 2008-03-04 |
Crohn Disease (2) · Psoriasis (1)
AbbVie (prior sponsor, Abbott) (5) · Abbott (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (7) · Canada (4) · Austria (3) · Belgium (3) · Denmark (3) · Finland (2) · France (2) · Germany (2) · Greece (2) · Italy (2) · Spain (2) · Sweden (2) · Switzerland (2) · United Kingdom (2) · Australia (1)
Martin Kaul, MD (5) · David A Williams, MD (1) · Joaquin Valdes, MD (1) · Roberto Carcereri, MD (1)
PMID 21574983, PMID 21574984, PMID 22029980, PMID 22169986
2008 (1)